Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE Inc. (BIOL) pioneers advanced laser solutions transforming dental care through minimally invasive technologies. This dedicated news hub provides investors and dental professionals with essential updates on product innovations, financial performance, and clinical developments.
Access real-time announcements including earnings reports, FDA clearances, partnership agreements, and technological breakthroughs. Our curated collection ensures transparent access to material events shaping BIOLASE's position in the $7B dental laser market.
Key updates cover regulatory milestones, patent filings, clinical trial results, and executive commentary. Discover how BIOLASE's Waterlase technology and Epic X platform continue redefining standards in laser dentistry through reduced recovery times and enhanced precision.
Bookmark this page for structured access to verified corporate communications. Monitor BIOLASE's progress in expanding global adoption of dental lasers while maintaining compliance with SEC disclosure requirements and medical device regulations.
BIOLASE, Inc. (NASDAQ: BIOL) announced a 1-for-25 reverse stock split effective April 28, 2022, to maintain its listing on the Nasdaq Capital Market. This move reduces outstanding shares from approximately 154 million to 6.2 million. The reverse stock split aims to increase BIOL's per-share trading price to meet Nasdaq's minimum bid requirement of $1.00. Shareholders will receive one new share for every 25 shares held, and no fractional shares will be issued. For further details, stockholders can refer to BIOLASE's proxy materials from the recent annual meeting.
BIOLASE, a leader in dental lasers, will participate in the 2022 Virtual Growth Conference by Maxim Group LLC from March 28 to 30. President and CEO John Beaver is set to join a fireside chat with analyst Anthony Vendetti on March 28 at 10:30 am ET. Attendees will gain insights from executives across various sectors, including healthcare and technology. This event will be accessible on M-Vest for registered members. BIOLASE specializes in innovative dental laser systems, enhancing dental procedures with advanced technology and superior performance.
BIOLASE, Inc. (NASDAQ: BIOL) reported strong financial results for 2021, with total revenue reaching $39.2 million, a 72% increase year-over-year. The fourth quarter alone saw revenue of $12.4 million, an increase of 46% from the previous year. U.S. laser sales increased 39%, while international laser sales surged 87%. Despite a net loss of $16.7 million for the year, BIOLASE maintains a robust balance sheet, ending 2021 with $30 million in cash. Looking ahead, the company anticipates a 10% revenue growth in 2022.
BIOLASE, a leader in dental lasers, will announce its fourth quarter and full-year 2021 financial results on March 17, 2022, after market close. A conference call will be held at 4:30 p.m. ET to discuss the results and corporate updates. Interested participants can dial in from the U.S. and Canada at (888) 254-3590 or internationally at +1 (323) 794-2551, using Conference ID 9127979. A webcast will also be available on the BIOLASE Investor Events Page. An audio archive will remain accessible for 30 days.
BIOLASE, Inc. (NASDAQ: BIOL) has announced a dividend distribution of one one-thousandth of a share of newly-designated Series G Preferred Stock for each outstanding share of common stock held by record on March 25, 2022. This preferred stock will have significant voting rights concerning a reverse stock split but will not be transferable except in connection with BIOLASE common stock transfers. Any unvoted series will be automatically redeemed. More details will follow in a Form 8-K.
BIOLASE, Inc. (NASDAQ: BIOL) reported preliminary fourth quarter revenue results for 2021, projecting earnings between $12.2 million and $12.5 million, marking a 44% to 47% increase year-over-year and 20% to 23% compared to Q4 2019. The company is well-positioned for growth with approximately $30.0 million in cash reserves. Key achievements include FDA approval for the new EdgePRO laser and strategic partnerships aimed at expanding laser adoption. BIOLASE anticipates further growth in 2022, focusing on increased adoption and sales within the dental community.
BIOLASE, Inc. (NASDAQ: BIOL) and EdgeEndo have received FDA 510(k) clearance for the EdgePRO Laser-Assisted Microfluidic Irrigation device, improving cleaning and disinfection in root canal procedures. This innovative system utilizes BIOLASE's patented Er,Cr:YSGG 2780 nm wavelength laser technology, ensuring effective removal of infected tissue and biofilms while maintaining cost efficiency. EdgeEndo will start selling the EdgePRO system in the U.S. immediately, reflecting a strong collaboration between the two companies aimed at elevating dental care quality.
BIOLASE, Inc. (NASDAQ: BIOL) announced its participation in the H.C. Wainwright BIOCONNECT Virtual Investor Conference from January 10-13, 2022. The company's President and CEO, John Beaver, will deliver a presentation and conduct virtual meetings with investors. A pre-recorded presentation will be available starting January 10, 2022, at 7 am ET. Interested parties can schedule one-on-one meetings by contacting BIOLASE's investor relations team via email.
BIOLASE develops and markets dental laser systems, offering innovative technology designed to enhance dental procedures.
